Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of subcutaneous CDX-0159 in healthy subjects
NCT05031624Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) comparing CDX-0159 with Placebo (2 arms). Primary endpoint: Safety as assessed by Toxicity Grading Scale. Started Aug 2021; status: completed.
02
Drugs
barzolvolimab
03
Conditions
chronic spontaneous urticaria (CSU)chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT05031624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031624.